Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma

T. Tsushima, M. Noda, Yasutomo Nasu, H. Ohmori, A. Yamamoto, H. Takigawa, S. Kagawa, Y. Matsumura, T. Matsumoto, I. Ogawa, A. Kawano, M. Nishi, S. Akazawa, S. Nakamura, K. Y. Akiyama, K. Tatara, Y. Sumiyoshi, Y. Aga, T. Yokota

Research output: Contribution to journalArticle

Abstract

A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).

Original languageEnglish
Pages (from-to)986-991
Number of pages6
JournalNishinihon Journal of Urology
Volume56
Issue number9
Publication statusPublished - 1994

Fingerprint

Mitomycin
Combination Drug Therapy
Renal Cell Carcinoma
Fluorouracil
Interferons
Fatigue
Bone Marrow
Survival
Therapeutics

Keywords

  • 5-fluorouracil
  • interferon-α
  • mitomycin C
  • renal cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Tsushima, T., Noda, M., Nasu, Y., Ohmori, H., Yamamoto, A., Takigawa, H., ... Yokota, T. (1994). Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma. Nishinihon Journal of Urology, 56(9), 986-991.

Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma. / Tsushima, T.; Noda, M.; Nasu, Yasutomo; Ohmori, H.; Yamamoto, A.; Takigawa, H.; Kagawa, S.; Matsumura, Y.; Matsumoto, T.; Ogawa, I.; Kawano, A.; Nishi, M.; Akazawa, S.; Nakamura, S.; Akiyama, K. Y.; Tatara, K.; Sumiyoshi, Y.; Aga, Y.; Yokota, T.

In: Nishinihon Journal of Urology, Vol. 56, No. 9, 1994, p. 986-991.

Research output: Contribution to journalArticle

Tsushima, T, Noda, M, Nasu, Y, Ohmori, H, Yamamoto, A, Takigawa, H, Kagawa, S, Matsumura, Y, Matsumoto, T, Ogawa, I, Kawano, A, Nishi, M, Akazawa, S, Nakamura, S, Akiyama, KY, Tatara, K, Sumiyoshi, Y, Aga, Y & Yokota, T 1994, 'Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma', Nishinihon Journal of Urology, vol. 56, no. 9, pp. 986-991.
Tsushima, T. ; Noda, M. ; Nasu, Yasutomo ; Ohmori, H. ; Yamamoto, A. ; Takigawa, H. ; Kagawa, S. ; Matsumura, Y. ; Matsumoto, T. ; Ogawa, I. ; Kawano, A. ; Nishi, M. ; Akazawa, S. ; Nakamura, S. ; Akiyama, K. Y. ; Tatara, K. ; Sumiyoshi, Y. ; Aga, Y. ; Yokota, T. / Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma. In: Nishinihon Journal of Urology. 1994 ; Vol. 56, No. 9. pp. 986-991.
@article{a20feff4439c48deb152689f1a00605a,
title = "Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma",
abstract = "A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6{\%}. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3{\%}), fatigue (70.8{\%}), flu-like symptoms (62.5{\%}) and bone marrow suppression (83.3{\%}).",
keywords = "5-fluorouracil, interferon-α, mitomycin C, renal cell carcinoma",
author = "T. Tsushima and M. Noda and Yasutomo Nasu and H. Ohmori and A. Yamamoto and H. Takigawa and S. Kagawa and Y. Matsumura and T. Matsumoto and I. Ogawa and A. Kawano and M. Nishi and S. Akazawa and S. Nakamura and Akiyama, {K. Y.} and K. Tatara and Y. Sumiyoshi and Y. Aga and T. Yokota",
year = "1994",
language = "English",
volume = "56",
pages = "986--991",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "9",

}

TY - JOUR

T1 - Interferon-α2B, 5-fluorouracil and mitomycin C combination chemotherapy for metastatic renal cell carcinoma

AU - Tsushima, T.

AU - Noda, M.

AU - Nasu, Yasutomo

AU - Ohmori, H.

AU - Yamamoto, A.

AU - Takigawa, H.

AU - Kagawa, S.

AU - Matsumura, Y.

AU - Matsumoto, T.

AU - Ogawa, I.

AU - Kawano, A.

AU - Nishi, M.

AU - Akazawa, S.

AU - Nakamura, S.

AU - Akiyama, K. Y.

AU - Tatara, K.

AU - Sumiyoshi, Y.

AU - Aga, Y.

AU - Yokota, T.

PY - 1994

Y1 - 1994

N2 - A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).

AB - A total of 24 patients with metastatic renal cell carcinoma were treated by recombinant interferon-α2b (IFN-α2b) in combination with 5-fluorouracil (5-FU) and mitomycin C (MMC). Combined treatment included IFN-α2b at 6 x 106 units per body, per day, administered intramuscularly, 5-FU at 500 mg/m2 per day, administered intravenously (days 1 to 5) and MMC 2 mg/m2 per day, administered intravenously (days 1 and 2), repeated every 28 days. Of the 22 evaluable patients, one showed CR and two showed PR, with a response rate of 13.6%. The response durations were 6, 7, and 40+ months. The median survival duration of eligible patients was 14.5 months (range 2 to 41+ months). The most frequent adverse reactions were gastrointestinal symptoms (83.3%), fatigue (70.8%), flu-like symptoms (62.5%) and bone marrow suppression (83.3%).

KW - 5-fluorouracil

KW - interferon-α

KW - mitomycin C

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0027940223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027940223&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027940223

VL - 56

SP - 986

EP - 991

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 9

ER -